Announcements Trials
Browse Landscape

Status

No longer available 1Available 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 265Observational 65Expanded_access 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 14Neoplasms 11Multiple Myeloma 10Recurrence 9Pancreatic Neoplasms 8Prostatic Neoplasms 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Ovarian Neoplasms 6Neuroblastoma 6Melanoma 6Leukemia, Myeloid, Acute 6Sarcoma 5Hematologic Neoplasms 4Glioblastoma 4Breast Neoplasms 4Stomach Neoplasms 3Osteosarcoma 3Non-Muscle Invasive Bladder Neoplasms 3Neuroectodermal Tumors, Primitive 3Myelodysplastic Syndromes 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Lung Neoplasms 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Carcinoma, Squamous Cell 3Uterine Neoplasms 2Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2

Interventions

tisagenlecleucel 1revumenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Expanded_access × Leukemia × 1 year × Clear all
NCT03601442 2026-04-23

Managed Access Programs for CTL019, Tisagenlecleucel

Novartis

Available
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

NCT05918913 2025-09-05

Expanded Access Program for Revumenib

Syndax Pharmaceuticals

No longer available
1 FDA
Other hematologic neoplasm

Leukemia, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡